Opaleye Management Inc.
James Silverman Boston, MA 22 13Fs · since 2021 Q3
- AUM $759M
- positions 53
- period 2026 Q1
- QoQ +0.1%
- top 5 44.1%
- qoq N 9 E 10 A 15 R 9
- HARROW INC 13.2%
- LIQUIDIA CORPORATION 11.7%
- ETON PHARMACEUTICALS INC 9.3%
- SOL-GEL TECHNOLOGIES LTD 5.2%
- RHYTHM PHARMACEUTICALS INC 4.7%
- APOGEE THERAPEUTICS INC - APGE 4.3%
- DISC MEDICINE INC - IRON 3.5%
- UROGEN PHARMA LTD 3.4%
- CRESCENT BIOPHARMA INC. 3.2%
- STOKE THERAPEUTICS INC 3.0%
- PERSPECTIVE THERAPEUTICS INC 2.6%
- REZOLUTE INC 2.5%
- Other 33.4%
AUM over time
Holdings value
2026 Q1
$759M
+0.1% QoQ
Latest book
| HARROW INC | 13.15% | Reduce −27.5% | 2,832,230 | $35.26 | $100M | −1,072,770 | −$91M |
| LIQUIDIA CORPORATION | 11.70% | Add +4.5% | 2,545,000 | $34.90 | $89M | +110,000 | +$4M |
| ETON PHARMACEUTICALS INC | 9.30% | 2,860,000 | $24.68 | $71M | — | — | |
| SOL-GEL TECHNOLOGIES LTD | 5.22% | Add +10.2% | 500,000 | $79.22 | $40M | +46,261 | +$20M |
| RHYTHM PHARMACEUTICALS INC | 4.65% | Reduce −62.7% | 123,000 | $287.18 | $35M | −207,000 | $— |
| APOGEE THERAPEUTICS INC - APGE | 4.32% | Add +0.4% | 390,000 | $84.17 | $33M | +1,743 | +$4M |
| DISC MEDICINE INC - IRON | 3.55% | Add +110.5% | 421,000 | $63.94 | $27M | +221,000 | +$11M |
| UROGEN PHARMA LTD | 3.39% | Add +432.7% | 1,430,000 | $17.98 | $26M | +1,161,577 | +$19M |
| CRESCENT BIOPHARMA INC. | 3.18% | Add +11.4% | 1,312,615 | $18.37 | $24M | +134,315 | +$10M |
| STOKE THERAPEUTICS INC | 3.00% | Add +0.7% | 700,000 | $32.56 | $23M | +5,000 | +$733 |
| PERSPECTIVE THERAPEUTICS INC | 2.57% | Add +294.7% | 4,675,000 | $4.17 | $19M | +3,490,500 | +$15M |
| REZOLUTE INC | 2.53% | Add +0.2% | 6,300,000 | $3.05 | $19M | +12,844 | +$4M |
| MEIRAGTX HLDGS PLC | 2.42% | Add +443.2% | 2,123,259 | $8.66 | $18M | +1,732,415 | +$15M |
| TG THERAPEUTICS INC | 2.34% | 535,000 | $33.22 | $18M | — | — | |
| SANUWAVE HEALTH INC | 2.23% | 981,267 | $17.29 | $17M | — | — | |
| EDGEWISE THERAPEUTICS INC | 2.07% | 500,000 | $31.50 | $16M | — | — | |
| ALPHA COGNITION INC - ACOG | 1.85% | Add +23.7% | 2,561,950 | $5.49 | $14M | +491,166 | +$605 |
| ANNEXON INC - ANNX | 1.70% | Reduce −10.3% | 2,331,761 | $5.54 | $13M | −268,239 | −$134 |
| ALUMIS INC - ALMS | 1.60% | Add +2.8% | 550,000 | $22.03 | $12M | +15,000 | +$7M |
| CODEXIS INC - CDXS | 1.46% | Reduce −0.1% | 6,785,000 | $1.63 | $11M | −4,738 | −$8 |
| PROTAGONIST THERAPEUTICS INC | 1.39% | Reduce −4.8% | 100,000 | $105.40 | $11M | −5,000 | +$1M |
| REVOLUTION MEDICINES INC - RVMD | 1.28% | 100,000 | $97.25 | $10M | — | — | |
| XOMA ROYALTY CORPORATION | 1.24% | Add +2.5% | 300,000 | $31.37 | $9M | +7,410 | +$2M |
| Q32 BIO INC | 1.06% | Add +488.8% | 1,256,228 | $6.42 | $8M | +1,042,865 | +$7M |
| MBX BIOSCIENCES INC | 1.02% | 260,000 | $29.85 | $8M | — | — | |
| RELMADA THERAPEUTICS INC | 0.86% | 935,000 | $6.96 | $7M | — | — | |
| CG ONCOLOGY INC - CGON | 0.85% | Reduce −76.9% | 94,800 | $67.68 | $6M | −315,200 | −$11M |
| JADE BIOSCIENCES INC - JBIO | 0.79% | 427,608 | $14.05 | $6M | — | — | |
| OCULAR THERAPEUTIX INC | 0.67% | Reduce −62.4% | 600,000 | $8.47 | $5M | −995,000 | −$14M |
| ASSERTIO HOLDINGS INC - AH30 | 0.67% | New | 265,707 | $19.06 | $5M | +265,707 | +$5M |
| EDITAS MEDICINE INC | 0.63% | New | 1,926,997 | $2.47 | $5M | +1,926,997 | +$5M |
| SUTRO BIOPHARMA INC | 0.63% | 190,671 | $24.91 | $5M | — | — | |
| JOURNEY MED CORP | 0.59% | Reduce −1.5% | 960,000 | $4.69 | $5M | −15,000 | −$3M |
| VOYAGER THERAPEUTICS INC | 0.58% | Reduce −3.9% | 1,150,000 | $3.86 | $4M | −46,904 | −$265 |
| TREVI THERAPEUTICS INC | 0.54% | 345,100 | $11.93 | $4M | — | — | |
| TECTONIC THERAPEUTIC INC | 0.50% | Reduce −42.7% | 123,000 | $30.91 | $4M | −91,747 | −$678 |
| CABALETTA BIO INC - CABA | 0.49% | Add +53.3% | 1,380,000 | $2.69 | $4M | +480,000 | +$2M |
| BIODESIX INC - BDSX | 0.45% | New | 238,047 | $14.50 | $3M | +238,047 | +$3M |
| ROCKET PHARMACEUTICALS INC | 0.45% | 955,000 | $3.58 | $3M | — | — | |
| ZENTALIS PHARMACEUTICALS INC | 0.44% | Add +0.8% | 1,412,656 | $2.34 | $3M | +11,750 | +$1M |
| INTELLIA THERAPEUTICS INC - INTC | 0.41% | New | 245,000 | $12.82 | $3M | +245,000 | +$3M |
| FORTRESS BIOTECH INC | 0.38% | Reduce −4.4% | 1,042,000 | $2.79 | $3M | −48,000 | −$1M |
| OPUS GENETICS INC | 0.30% | 1,120,000 | $2.01 | $2M | — | — | |
| RIGEL PHARMACEUTICALS INC | 0.25% | 70,000 | $27.04 | $2M | — | — | |
| ATEA PHARMACEUTICALS INC - AVIR | 0.23% | Add +79.4% | 322,600 | $5.38 | $2M | +142,785 | +$1M |
| LYELL IMMUNOPHARMA INC | 0.21% | New | 79,097 | $20.06 | $2M | +79,097 | +$2M |
| ENANTA PHARMACEUTICALS INC | 0.21% | Add +66.7% | 125,000 | $12.63 | $2M | +50,000 | +$396 |
| NEXTCURE INC | 0.20% | New | 141,181 | $10.68 | $2M | +141,181 | +$2M |
| 4D MOLECULAR THERAPEUTICS IN | 0.14% | New | 112,291 | $9.31 | $1M | +112,291 | +$1M |
| PROTALIX BIOTHERAPEUTICS INC | 0.10% | Reduce −86.3% | 340,000 | $2.17 | $738 | −2,138,176 | −$4M |
| ALKERMES PLC | — | Exit | 0 | $27.98 | — | −490,000 | −$14M |
| GOSSAMER BIO INC | — | Exit | 0 | $3.10 | — | −2,720,000 | −$8M |
| KARYOPHARM THERAPEUTICS INC | — | Exit | 0 | $7.36 | — | −930,000 | −$7M |
| ZYMEWORKS INC | — | Exit | 0 | $26.33 | — | −108,929 | −$3M |
| ASSERTIO HOLDINGS INC | — | Exit | 0 | $9.07 | — | −285,000 | −$3M |
| VENTYX BIOSCIENCES INC | — | Exit | 0 | $9.03 | — | −251,932 | −$2M |
| GENERATION BIO CO | — | Exit | 0 | $5.68 | — | −310,000 | −$2M |
| BRIDGEBIO PHARMA INC - BBIO | — | Exit | 0 | $76.48 | — | −18,319 | −$1M |
| SILENCE THERAPEUTICS PLC | — | Exit | 0 | $6.08 | — | −78,926 | −$480 |
| RAPT THERAPEUTICS INC | — | Exit | 0 | $1.42 | — | −150,000 | −$213 |
Showing top 50 of 53 by value · full holdings → · all activity →
* Reported price is value ÷ shares from the 13F as of period end — not a live market quote. Weight % is each long-equity position ÷ full 13F AUM, so rows may not sum to 100% when the filing includes options or other non-equity (excluded from this table). Share change and $ change are vs 2025 Q4. Click column headers to sort · click New / Exit / Add / Reduce to promote that move type to the top. Among managers we track.
filings history
22 periods · normalized AUM · click period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q1 | 54 | $759M | +0.1% | 13F-HR | 5/15/2026 | 000142050626001151 |
| 2025 Q4 | 54 | $758M | — | RESTATEMENT | 4/13/2026 | 000149315226016299 |
| 2025 Q4 | 54 | $758M | +7.2% | 13F-HR | 2/17/2026 | 000149315226007085 |
| 2025 Q3 | 43 | $707M | +41.7% | 13F-HR | 11/14/2025 | 000149315225023429 |
| 2025 Q2 | 41 | $494M | — | RESTATEMENT | 8/15/2025 | 000164117225024301 |
| 2025 Q2 | 41 | $499M | +11.1% | 13F-HR | 8/14/2025 | 000164117225023977 |
| 2025 Q1 | 45 | $449M | −21.4% | 13F-HR | 5/15/2025 | 000164117225010914 |
| 2024 Q4 | 39 | $571M | −4.8% | 13F-HR | 2/14/2025 | 000149315225006852 |
| 2024 Q3 | 44 | $600M | +37.0% | 13F-HR | 11/14/2024 | 000149315224045811 |
| 2024 Q2 | 51 | $438M | +0.2% | 13F-HR | 8/14/2024 | 000149315224032150 |
| 2024 Q1 | 52 | $459M | — | RESTATEMENT | 5/29/2024 | 000149315224021780 |
| 2024 Q1 | 51 | $437M | +16.2% | 13F-HR | 5/15/2024 | 000149315224019869 |
| 2023 Q4 | 47 | $376M | +22.5% | 13F-HR | 2/14/2024 | 000149315224006653 |
| 2023 Q3 | 41 | $307M | −26.6% | 13F-HR | 11/15/2023 | 000149315223041364 |
| 2023 Q2 | 47 | $418M | +25.1% | 13F-HR | 8/14/2023 | 000149315223028636 |
| 2023 Q1 | 41 | $334M | +16.0% | 13F-HR | 5/15/2023 | 000149315223016769 |
| 2022 Q4 | 40 | $288M | +19.0% | 13F-HR | 2/10/2023 | 000149315223004277 |
| 2022 Q3 | 42 | $242M | +9.0% | 13F-HR | 11/14/2022 | 000149315222032068 |
| 2022 Q2 | 47 | $222M | −31.1% | 13F-HR | 8/15/2022 | 000149315222022856 |
| 2022 Q1 | 45 | $322M | −31.6% | 13F-HR | 5/16/2022 | 000149315222013764 |
| 2021 Q4 | 39 | $471M | −12.0% | 13F-HR | 2/14/2022 | 000149315222004434 |
| 2021 Q3 | 48 | $535M | — | 13F-HR | 11/16/2021 | 000149315221028799 |
About
Opaleye Management Inc.
22 processed 13Fs · since 2021 Q3